JP2022520596A - 前立腺がんを治療するための新規マーカーとしてのｅｐｈｂ４－エフリンｂ２受容体リガンド対 - Google Patents

前立腺がんを治療するための新規マーカーとしてのｅｐｈｂ４－エフリンｂ２受容体リガンド対 Download PDF

Info

Publication number
JP2022520596A
JP2022520596A JP2021547322A JP2021547322A JP2022520596A JP 2022520596 A JP2022520596 A JP 2022520596A JP 2021547322 A JP2021547322 A JP 2021547322A JP 2021547322 A JP2021547322 A JP 2021547322A JP 2022520596 A JP2022520596 A JP 2022520596A
Authority
JP
Japan
Prior art keywords
treatment
ephb4
cancer
sephb4
refractory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547322A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020168110A5 (https=
JP2022520596A5 (https=
Inventor
クラスノペロフ，ヴァレリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasgene Therapeutics Inc
Original Assignee
Vasgene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasgene Therapeutics Inc filed Critical Vasgene Therapeutics Inc
Publication of JP2022520596A publication Critical patent/JP2022520596A/ja
Publication of JPWO2020168110A5 publication Critical patent/JPWO2020168110A5/ja
Publication of JP2022520596A5 publication Critical patent/JP2022520596A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021547322A 2019-02-13 2020-02-13 前立腺がんを治療するための新規マーカーとしてのｅｐｈｂ４－エフリンｂ２受容体リガンド対 Pending JP2022520596A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805291P 2019-02-13 2019-02-13
US62/805,291 2019-02-13
PCT/US2020/018160 WO2020168110A1 (en) 2019-02-13 2020-02-13 Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer

Publications (3)

Publication Number Publication Date
JP2022520596A true JP2022520596A (ja) 2022-03-31
JPWO2020168110A5 JPWO2020168110A5 (https=) 2023-02-21
JP2022520596A5 JP2022520596A5 (https=) 2023-02-21

Family

ID=72045655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547322A Pending JP2022520596A (ja) 2019-02-13 2020-02-13 前立腺がんを治療するための新規マーカーとしてのｅｐｈｂ４－エフリンｂ２受容体リガンド対

Country Status (8)

Country Link
US (1) US20220153791A1 (https=)
EP (1) EP3923969A4 (https=)
JP (1) JP2022520596A (https=)
KR (1) KR20220010469A (https=)
CN (1) CN114007633A (https=)
AU (1) AU2020221276A1 (https=)
CA (1) CA3139416A1 (https=)
WO (1) WO2020168110A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2020190977A1 (en) * 2019-03-17 2020-09-24 Vasgene Therapeutics Inc Treatment of cancers using sephb4-hsa fusion proteins
CA3211742A1 (en) * 2021-03-18 2022-09-22 Valery Krasnoperov Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment
CN118290563B (zh) * 2024-06-03 2024-08-02 磐如生物科技(天津)有限公司 一种前列腺癌抗原肽和免疫佐剂组合物及其在抗肿瘤中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514618A (ja) * 2004-09-23 2008-05-08 バスジーン セラピューティクス， インコーポレイテッド 血管形成及び腫瘍増殖阻害用ポリペプチド化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
WO2012068477A1 (en) * 2010-11-19 2012-05-24 Vasgene Therapeutics, Inc. Methods and compositions for inhibiting angiogenesis and tumor growth
EP2922861A4 (en) * 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
WO2020190977A1 (en) * 2019-03-17 2020-09-24 Vasgene Therapeutics Inc Treatment of cancers using sephb4-hsa fusion proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514618A (ja) * 2004-09-23 2008-05-08 バスジーン セラピューティクス， インコーポレイテッド 血管形成及び腫瘍増殖阻害用ポリペプチド化合物

Also Published As

Publication number Publication date
KR20220010469A (ko) 2022-01-25
CA3139416A1 (en) 2020-08-20
US20220153791A1 (en) 2022-05-19
WO2020168110A1 (en) 2020-08-20
EP3923969A1 (en) 2021-12-22
CN114007633A (zh) 2022-02-01
AU2020221276A1 (en) 2021-10-07
EP3923969A4 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
JP2022520596A (ja) 前立腺がんを治療するための新規マーカーとしてのｅｐｈｂ４－エフリンｂ２受容体リガンド対
US11253571B2 (en) Preventive or therapeutic agent for kidney disease
US10786545B2 (en) Use of peptides that block metadherin-SND1 interaction as treatment for cancer
US20210046109A1 (en) Suppressive Exosomes in Cancer and for Immunosuppression
EP2870970B1 (en) Prophylactic or therapeutic agent for hepatic diseases
JP2020519298A (ja) バイシストロン性キメラ抗原受容体及びそれらの使用
JP7684692B2 (ja) 低酸素応答性キメラ抗原受容体
JP2014529298A (ja) Ｐｉｋ３ｃａｈ１０４７ｒノックイン非ヒト動物乳癌モデル
Tan et al. Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities
US20220054614A1 (en) Inhibition of asph expressing tumor growth and progression
US10195166B2 (en) Methods for treating hepatitis C virus infectious disease
HK40068256A (en) Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer
Chitra et al. Generation and characterization of JSRV envelope transgenic mice in FVB background
US11596655B2 (en) Activation of natural cytotoxicity receptor 2 (NCR2)
WO2022059703A1 (ja) がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法
US20260053891A1 (en) Methods and compositions for treating cancer
WO2007010628A1 (ja) 癌の予防・治療剤
US10870690B2 (en) Protein therapeutant and method for treating cancer
Diep Therapeutic Targeting of AXL/Gas6 Signaling in Metastatic and Primary Cancer
JP2016501856A (ja) 乳癌を処置するためのｃｄ４４ｖ６由来ペプチド
Liu Immunotherapy for Desmoplastic Melanoma: Nano-medicine Approaches of Vaccination and Immune-modulation
HK1232431A1 (en) Preventive or therapeutic agent for kidney disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240827